GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 4basebio PLC (XTER:88Q) » Definitions » Total Long-Term Assets

4basebio (XTER:88Q) Total Long-Term Assets : €7.56 Mil (As of Jun. 2023)


View and export this data going back to 2021. Start your Free Trial

What is 4basebio Total Long-Term Assets?

Total Long-Term Assets includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets. 4basebio's Total Long-Term Assets for the quarter that ended in Jun. 2023 was €7.56 Mil.


4basebio Total Long-Term Assets Historical Data

The historical data trend for 4basebio's Total Long-Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

4basebio Total Long-Term Assets Chart

4basebio Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Total Long-Term Assets
0.66 2.54 4.78 6.66

4basebio Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Total Long-Term Assets Get a 7-Day Free Trial 2.88 4.78 6.42 6.66 7.56

4basebio Total Long-Term Assets Calculation

Total Long-Term Assets are the sum of the carrying amounts of all assets that are expected to be realized in cash, sold or consumed longer than one year. It includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets.


4basebio Total Long-Term Assets Related Terms

Thank you for viewing the detailed overview of 4basebio's Total Long-Term Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


4basebio (XTER:88Q) Business Description

Traded in Other Exchanges
Address
25 Norman Way, Over, Cambridge, GBR, CB24 5QE
4basebio PLC is a life sciences group focused on therapeutic DNA for gene therapies and DNA vaccines and providing solutions for the effective and safe delivery of these DNA-based products to patients. Its country of operation is the UK. It is engaged in the manufacturing and supply of high-purity, synthetic DNA for research, therapeutic and pharmacological use.

4basebio (XTER:88Q) Headlines

No Headlines